骨髓增生异常综合征患者PTPN11基因表达及突变的临床意义

周立宇; 许峰; 吴凌云; 贺琪; 张征; 李晓; 常春康

doi:10.13201/j.issn.1004-2806.2019.01.009

骨髓增生异常综合征患者PTPN11基因表达及突变的临床意义

- 上海交通大学附属第六人民医院血液内科(上海, 200233)

详细信息

通讯作者: 常春康,E-mail:changchunkang7010@aliyun.com

中图分类号: R733.7

收稿日期: 2018-11-08

Clinical analysis of PTPN11 gene expression and mutation in myelodysplastic syndromes

- Department of Hematology, the Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, 200233, China

More Information

Corresponding author: CHANG Chunkang, E-mail: changchunkang7010@aliyun.com

Received Date: 08 November 2018

摘要

摘要: 目的:探讨骨髓增生异常综合征(MDS)患者PTPN11基因表达特征及其临床意义。方法:采用SYBR Green染料标记定量PCR分析123例MDS患者和30例良性血细胞减少患者骨髓单个核细胞PTPN11 mRNA表达;同时采用基于Miseq平台的二代测序法检测上述患者PTPN11全外显子突变情况。结果:与良性对照相比,MDS患者PTPN11基因表达水平明显增高(P=0.009)。按照WHO分类,低危和高危MDS患者PTPN11基因表达水平均高于良性对照(P=0.001;P=0.005),然而低危和高危MDS患者之间PTPN11表达无差别;按照IPSS-R预后分类,较低危、中危和高危MDS患者PTPN11表达水平均高于良性对照(P=0.001;P=0.006;P<0.001),而高危MDS患者PTPN11表达水平高于较低危和中危MDS患者(P=0.003;P=0.004)。根据对照组PTPN11基因表达水平平均值加两个标准差,将MDS患者分为PTPN11高表达组和低表达组。临床分析显示PTPN11高表达组患者外周血中性粒细胞计数、骨髓增殖度、IPSS-R积分风险以及白血病转化率显著高于PTPN11低表达组(P=0.001;P=0.016;P=0.014;P<0.001)。生存分析显示,与PTPN11低表达组患者相比,PTPN11高表达组患者呈现相对缩短的总生存时间(P=0.052)以及明显缩短的无白血病生存时间(P=0.017)。二代测序揭示123例MDS患者存在3例(2.4%)PTPN11突变,均为错义突变(1例p.A72V和2例p.D61V),3例均为RAEB-2患者且最终转化为急性髓系白血病,生存时间均未超过18个月。结论:MDS患者PTPN11基因表达水平增高,预示患者较高的肿瘤增殖度和白血病转化风险;MDS患者PTPN11基因突变频率较低,一旦发生预后较差。
- 骨髓增生异常综合征 /
- PTPN11 /
- 基因表达 /
- 突变 /
- 预后
Abstract: Objective:To investigate the prevalence and clinical characteristics of PTPN11 gene expression and mutations in myelodysplastic syndromes (MDS).Method:The expression of PTPN11 was determined by quantitive PCR based on SYBR green binding in 123 patients with MDS and 30 controls with benign cytopenias.Next-generation sequencing was used to determine the PTPN11 mutations located in all exons.Result:Compared with benign controls,PTPN11 gene expression was significantly increased in MDS patients (P=0.009).According to WHO classification,the expressions of PTPN11 in both low-grade and high-grade MDS were higher than that in controls (P=0.001;P=0.005).However,there was no significant difference in PTPN11 expression between low-grade and high-grade MDS.According to IPSS-R prognosis classification,PTPN11 expressions in lower-risk,intermedi-ate-risk and high-risk MDS patients were all higher than that in controls (P=0.001;P=0.006;P<0.001),and the PTPN11 expression in high-risk MDS patients was higher than those in lower-risk or intermediate-risk patients (P=0.003;P=0.004).Based on the mean value of PTPN11 gene expression level in controls plus two standard deviations,the MDS patients were divided into PTPN11 high expression group and low expression group.Clinical analysis showed that peripheral blood neutrophil count,bone marrow cellularity,IPSS-R score and leukemia transformation rate were significantly higher in the PTPN11 high expression group than those in the low expression group (P=0.001;P=0.016;P=0.014;P<0.001).Survival analysis showed that patients with high PTPN11 expression showed a relatively shorter overall survival (P=0.052) and a significantly shorter leukemia-free survival time (P=0.017) comparing to patients with low PTPN11 expression.The next-generation sequencing revealed PTPN11 mutations in 3 cases (2.4%) among 123 patients with MDS,all of which were missense mutations (one case of p.A72V and two cases of p.D61V),and all three cases were RAEB-2 patients and eventually converted to AML with less than 18 months of survival time.Conclusion:The expression level of PTPN11 gene in patients with MDS is increased,which predicts higher tumor proliferation and risk of leukemia transformation.PTPN11 mutations predict worse prognosis in spite of low frequency in MDS.
- myelodysplastic syndromes /
- PTPN11 /
- gene expression /
- mutation /
- prognosis

HTML全文

参考文献(19)

[1]	Pandey R, Saxena M, Kapur R.Role of SHP2 in hematopoiesis and leukemogenesis[J].Curr Opin Hematol, 2017, 24:307-313.
[2]	Zhang J, Zhang F, Niu R.Functions of Shp2in cancer[J].J Cell Mol Med, 2015, 19:2075-2083.
[3]	Nabinger SC, Chan RJ.Shp2 function in hematopoietic stem cell biology and leukemogenesis[J].Curr Opin Hematol, 2012, 19:273-279.
[4]	Li L, Modi H, McDonald T, et al.A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells[J].Blood, 2011, 118:1504-1515.
[5]	Chan G, Cheung LS, Yang W, et al.Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells[J].Blood, 2011, 117:4253-4261.
[6]	Tartaglia M, Mehler EL, Goldberg R, et al.Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome[J].Nat Genet, 2001, 29:465-468.
[7]	Tartaglia M, Niemeyer CM, Fragale A, et al.Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia[J].Nat Genet, 2003, 34:148-150.
[8]	Vardiman JW, Thiele J, Arber DA, et al.The 2008revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia:rationale and important changes[J].Blood, 2009, 114:937-951.
[9]	Greenberg P, Cox C, LeBeau MM, et al.International scoring system for evaluating prognosis in myelodysplastic syndromes[J].Blood, 1997, 89:2079-2088.
[10]	Greenberg PL, Tuechler H, Schanz J, et al.Revised international prognostic scoring system for myelodysplastic syndromes[J].Blood, 2012, 120:2454-2465.
[11]	肖志坚.骨髓增生异常综合征的精准诊断与治疗:现况与问题[J].临床血液学杂志, 2017, 30 (5):339-341.
[12]	Braun BS, Tuveson DA, Kong N, et al.Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder[J].Proc Natl Acad Sci U S A, 2004, 101:597-602.
[13]	Akutagawa J, Huang TQ, Epstein I, et al.Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras[J].Leukemia, 2016, 30:1335-1343.
[14]	Ivins Zito C, Kontaridis M, Fornaro MJ, et al.SHP-2regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis[J].Cell Physiol, 2004, 199:227-236.
[15]	Niimi H, Harada H, Harada Y, et al.Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations[J].Leukemia, 2006, 20:635-644.
[16]	Wang H, Lindsey S, Konieczna I, et al.Constitutively active SHP2 cooperates with HoxA1 0overexpression to induce acute myeloid leukemia[J].J Biol Chem, 2009, 284:2549-2567.
[17]	Tefferi A, Gilliland DG.Oncogenes in myeloproliferative disorders[J].Cell Cycle, 2007, 6:550-566.
[18]	Xu R, Yu Y, Zheng S, et al.Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia[J].Blood, 2005, 106:3142-3149.
[19]	Watkins F, Fidler C, Boultwood J, et al.Mutations in PTPN1 1are rare in adult myelodysplastic syndromes and acute myeloid leukemia[J].Am J Hematol, 2004, 76:417.